NO803916L - Fremgangsmaate ved fremstilling av en terapeutisk virksom blanding - Google Patents
Fremgangsmaate ved fremstilling av en terapeutisk virksom blandingInfo
- Publication number
- NO803916L NO803916L NO803916A NO803916A NO803916L NO 803916 L NO803916 L NO 803916L NO 803916 A NO803916 A NO 803916A NO 803916 A NO803916 A NO 803916A NO 803916 L NO803916 L NO 803916L
- Authority
- NO
- Norway
- Prior art keywords
- preparing
- procedure
- animals
- ester
- therapeutic active
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 6
- 230000001225 therapeutic effect Effects 0.000 title description 7
- 238000000034 method Methods 0.000 title description 3
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 3
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 5
- -1 L-arginine ester Chemical class 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000020931 dietary conditions Nutrition 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT28417/79A IT1127322B (it) | 1979-12-28 | 1979-12-28 | Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO803916L true NO803916L (no) | 1981-06-29 |
Family
ID=11223560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO803916A NO803916L (no) | 1979-12-28 | 1980-12-23 | Fremgangsmaate ved fremstilling av en terapeutisk virksom blanding |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US4282217A (sv) |
| JP (1) | JPS56103113A (sv) |
| AR (1) | AR224288A1 (sv) |
| AU (1) | AU524820B2 (sv) |
| BE (1) | BE886758A (sv) |
| BR (1) | BR8008493A (sv) |
| CA (1) | CA1161362A (sv) |
| DE (1) | DE3027039C2 (sv) |
| DK (1) | DK524080A (sv) |
| ES (1) | ES497508A0 (sv) |
| FI (1) | FI803767L (sv) |
| FR (1) | FR2472388A1 (sv) |
| GB (1) | GB2066072B (sv) |
| GR (1) | GR72504B (sv) |
| IE (1) | IE50549B1 (sv) |
| IN (1) | IN152354B (sv) |
| IT (1) | IT1127322B (sv) |
| LU (1) | LU83029A1 (sv) |
| NL (1) | NL182775C (sv) |
| NO (1) | NO803916L (sv) |
| PH (1) | PH17384A (sv) |
| PT (1) | PT72274B (sv) |
| SE (1) | SE8009103L (sv) |
| ZA (1) | ZA807516B (sv) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1201511B (it) * | 1985-12-23 | 1989-02-02 | Italfarmaco Spa | Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono |
| JPS6310084U (sv) * | 1986-07-07 | 1988-01-22 | ||
| US5059712A (en) * | 1989-09-13 | 1991-10-22 | Cornell Research Foundation, Inc. | Isolating aminoarginine and use to block nitric oxide formation in body |
| US5312835A (en) * | 1989-09-13 | 1994-05-17 | Board Of Regents, The University Of Texas System | Use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension |
| US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| US5028627A (en) * | 1989-09-13 | 1991-07-02 | Cornell Research Foundation, Inc. | Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
| US5770623A (en) * | 1989-09-13 | 1998-06-23 | Board Of Regents, The University Of Texas System | Argine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
| US5158883A (en) * | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
| GB8929076D0 (en) * | 1989-12-22 | 1990-02-28 | Scras | Treatment of shock by blocking agents of edrf effect or formation |
| US5196195A (en) * | 1990-03-27 | 1993-03-23 | Cornell Research Foundation, Inc. | Use of arginase to control nitric oxide formation |
| US5395612A (en) * | 1990-03-27 | 1995-03-07 | Cornell Research Foundation, Inc. | Method for treating systemic hypotension caused by sepsis or cytokine using arginase in combination with an α1 adrenergic agonist |
| SE468881B (sv) * | 1991-01-09 | 1993-04-05 | Kabi Pharmacia Ab | Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar |
| US5273875A (en) * | 1991-03-22 | 1993-12-28 | Cornell Research Foundation, Inc. | N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body |
| US5132453A (en) * | 1991-03-22 | 1992-07-21 | Cornell Research Foundation, Inc. | N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body |
| US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
| JP2534423B2 (ja) | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤 |
| US5877176A (en) * | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| US5281627A (en) * | 1992-05-28 | 1994-01-25 | Cornell Research Foundation, Inc. | Substituted arginines and substituted homoarginines and use thereof |
| US5585402A (en) * | 1992-12-23 | 1996-12-17 | Glaxo Wellcome Inc. | Nitric oxide synthase inhibitors |
| US20020031513A1 (en) * | 1997-11-24 | 2002-03-14 | Shamir Leibovitz | Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
| KR100472303B1 (ko) * | 2002-05-21 | 2005-03-08 | 김영미 | 결장표적성 프로드럭으로서의 코티코스테로이드21-설페이트 소듐 유도체 |
| US8439922B1 (en) | 2008-02-06 | 2013-05-14 | NiVasive, Inc. | Systems and methods for holding and implanting bone anchors |
| US9198698B1 (en) | 2011-02-10 | 2015-12-01 | Nuvasive, Inc. | Minimally invasive spinal fixation system and related methods |
| US9486256B1 (en) | 2013-03-15 | 2016-11-08 | Nuvasive, Inc. | Rod reduction assemblies and related methods |
| US9974577B1 (en) | 2015-05-21 | 2018-05-22 | Nuvasive, Inc. | Methods and instruments for performing leveraged reduction during single position spine surgery |
| US10398481B2 (en) | 2016-10-03 | 2019-09-03 | Nuvasive, Inc. | Spinal fixation system |
| US11051861B2 (en) | 2018-06-13 | 2021-07-06 | Nuvasive, Inc. | Rod reduction assemblies and related methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
| CA939265A (en) * | 1967-11-18 | 1974-01-01 | Yoshitaka Ikezuki | Injectable compositions for alleviating the pain incurred from administrations of injections |
| US3639585A (en) * | 1968-03-29 | 1972-02-01 | Res Inst Medicine Chem | Method of preventing corticosteroid-induced adverse effects on bon and compositions useful in said method |
| JPS5035061A (sv) * | 1973-07-28 | 1975-04-03 |
-
1979
- 1979-12-28 IT IT28417/79A patent/IT1127322B/it active
-
1980
- 1980-06-25 US US06/162,686 patent/US4282217A/en not_active Expired - Lifetime
- 1980-07-17 DE DE3027039A patent/DE3027039C2/de not_active Expired
- 1980-12-02 ZA ZA00807516A patent/ZA807516B/xx unknown
- 1980-12-02 GR GR63528A patent/GR72504B/el unknown
- 1980-12-03 FI FI803767A patent/FI803767L/fi not_active Application Discontinuation
- 1980-12-03 AU AU65029/80A patent/AU524820B2/en not_active Ceased
- 1980-12-03 CA CA000366085A patent/CA1161362A/en not_active Expired
- 1980-12-04 AR AR283476A patent/AR224288A1/es active
- 1980-12-05 ES ES497508A patent/ES497508A0/es active Granted
- 1980-12-09 DK DK524080A patent/DK524080A/da not_active Application Discontinuation
- 1980-12-10 NL NLAANVRAGE8006707,A patent/NL182775C/xx not_active IP Right Cessation
- 1980-12-11 IN IN1368/CAL/80A patent/IN152354B/en unknown
- 1980-12-12 IE IE2605/80A patent/IE50549B1/en unknown
- 1980-12-15 PH PH24982A patent/PH17384A/en unknown
- 1980-12-18 GB GB8040636A patent/GB2066072B/en not_active Expired
- 1980-12-19 BE BE2/58913A patent/BE886758A/nl not_active IP Right Cessation
- 1980-12-22 LU LU83029A patent/LU83029A1/de unknown
- 1980-12-23 PT PT72274A patent/PT72274B/pt unknown
- 1980-12-23 BR BR8008493A patent/BR8008493A/pt unknown
- 1980-12-23 NO NO803916A patent/NO803916L/no unknown
- 1980-12-23 SE SE8009103A patent/SE8009103L/sv not_active Application Discontinuation
- 1980-12-24 FR FR8027470A patent/FR2472388A1/fr active Granted
- 1980-12-26 JP JP18943780A patent/JPS56103113A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| AU524820B2 (en) | 1982-10-07 |
| US4282217A (en) | 1981-08-04 |
| GB2066072A (en) | 1981-07-08 |
| DE3027039C2 (de) | 1984-05-17 |
| BR8008493A (pt) | 1981-07-14 |
| AU6502980A (en) | 1981-07-02 |
| FR2472388A1 (fr) | 1981-07-03 |
| LU83029A1 (de) | 1981-03-27 |
| NL182775C (nl) | 1988-05-16 |
| FI803767L (fi) | 1981-06-29 |
| GB2066072B (en) | 1984-02-01 |
| AR224288A1 (es) | 1981-11-13 |
| DE3027039A1 (de) | 1981-07-02 |
| SE8009103L (sv) | 1981-06-29 |
| ES8205417A1 (es) | 1982-06-16 |
| DK524080A (da) | 1981-06-29 |
| ES497508A0 (es) | 1982-06-16 |
| PT72274A (en) | 1981-01-01 |
| FR2472388B1 (sv) | 1983-04-01 |
| PT72274B (en) | 1981-11-05 |
| JPS56103113A (en) | 1981-08-18 |
| IE50549B1 (en) | 1986-05-14 |
| NL182775B (nl) | 1987-12-16 |
| PH17384A (en) | 1984-08-06 |
| CA1161362A (en) | 1984-01-31 |
| IN152354B (sv) | 1983-12-24 |
| IT7928417A0 (it) | 1979-12-28 |
| ZA807516B (en) | 1981-11-25 |
| JPS6144844B2 (sv) | 1986-10-04 |
| NL8006707A (nl) | 1981-07-16 |
| BE886758A (nl) | 1981-04-16 |
| GR72504B (sv) | 1983-11-15 |
| IE802605L (en) | 1981-06-28 |
| IT1127322B (it) | 1986-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO803916L (no) | Fremgangsmaate ved fremstilling av en terapeutisk virksom blanding | |
| Kuroda et al. | Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in Triton WR-1339-induced hyperlipidemia | |
| LU85594A1 (de) | Oligodeoxynucleotide und polydeoxynucleotide,die mit einem bereich einer bei der virusvermehrung synthetisierten mrna hybridisieren und ihre anwendung als therapeutische wirkstoffe | |
| Thomson et al. | Inhibition of immediate hypersensitivity reactions by disodium cromoglycate. Requirements for activity in two laboratory models | |
| RO108220B1 (ro) | Preparate farmaceutice,pentru combaterea carceilor musculari si procedeu de obtinere a acestora | |
| Gitlin et al. | Site of catabolism of serum albumin | |
| WO1997038693A1 (en) | Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions | |
| Banik et al. | Effect of Steroidal Anti-Progestins on Implantation of Fertilized Eggs of Rats and Mice. | |
| Broome et al. | A new drug for the treatment of fascioliasis in sheep and cattle | |
| JPH0778021B2 (ja) | 下痢症ウイルス感染阻害剤 | |
| NO803918L (no) | Fremgangsmaate ved fremstilling av nye estere av arginin | |
| DE69716914T2 (de) | Behandlung und prophylaxe von unerwünschten effekten reaktiver sauerstoffverbindungen | |
| Jones et al. | Antifertility and dominant lethal mutation studies in male rats with dl-α-chlorohydrin and an amino-analogue | |
| JPH03294230A (ja) | 子宮内膜症治療剤 | |
| US5854287A (en) | D-Propranolol metabolites useful for antioxidant activities | |
| US3175943A (en) | Process for stimulating choleresis | |
| WO1990003172A2 (en) | Bile acids for treatment of viral infections | |
| CN107652265B (zh) | 1-(哌啶-4-基)-2-苯并咪唑酮类化合物及其应用 | |
| Margolis et al. | Cure of Experimental Canine Blacktongue with Optimal and Minimal Doses of Nicotinic Acid: Three Figures | |
| JPS5970615A (ja) | 口唇疱疹治療へのウンデシレン酸の使用 | |
| Starr et al. | Further evidence for the involvement of kinin in anaphylactic shock in the rat | |
| Pollard et al. | Oncolytic effect of viruses in tissue cultures. | |
| EP0121856A2 (de) | Verwendung von Pyrazolonderivaten bei der Bekämpfung des Wachstums von Tumorzellen und der Metastasenbildung, Arzneimittel hierfür und Verfahren zu deren Herstellung | |
| US2992165A (en) | Method of potentiating acth preparations | |
| JP4190216B2 (ja) | 紫外線誘発突然変異抑制剤および紫外線誘発突然変異抑制用皮膚外用剤 |